Clinical Trials
15 trialsNCT02491632 2026-03-18
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT03367156 2025-11-12
Dexamethasone in Controlling Dyspnea in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03590652 2025-10-21
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Terminated
NCT00588835 2020-11-30
ACE
Radboud University Medical Center
Phase 4 Terminated
NCT02815319 2020-04-28
REaCT-dex
Ottawa Hospital Research Institute
Phase 4 Completed
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00248547 2017-05-09
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
Phase NA Completed
NCT00609765 2017-03-23
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT02257476 2017-02-07
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
Emory University
Phase 1 Completed
NCT01490060 2016-04-11
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
M.D. Anderson Cancer Center
Phase NA Completed
NCT00250718 2015-08-03
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00438828 2014-11-19
Dexamethasone for the Prophylaxis of Pain Flare Study
Sunnybrook Health Sciences Centre
Phase 1 Completed
NCT01640340 2013-11-07
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Ohio State University Comprehensive Cancer Center
Phase NA Completed